Upstream Bio initiated with an Overweight at Piper Sandler
The Fly

Upstream Bio initiated with an Overweight at Piper Sandler

Piper Sandler initiated coverage of Upstream Bio (UPB) with an Overweight rating and $75 price target The analyst believes Upstream’s verekitug has a differentiated mechanism of action that targets the TSLP receptor versus ligand. Accordingly, the TSLP ligand has been de-risked by Tezspire’s 2021 approval in severe asthma, which represents a rapidly growing biologic market opportunity of $7.5B, the analyst tells investors in a research note.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App